Aurigene is a wholly-owned independent subsidiary of Dr. Reddy’s Laboratories.
G V PRASAD - CHAIRMAN OF THE BOARD
Mr. G V Prasad is the Co-Chairman and Managing Director of Dr. Reddy’s Laboratories Ltd. Prasad is widely credited as the architect of Dr. Reddy’s successful global generics strategy. He envisioned new business platforms like the Custom Pharmaceutical Services business and Specialty Pharmaceuticals and is dedicated to building the innovation side of the business. He is also a champion of sustainability thinking. Prasad earned his degree in Chemical Engineering from the Illinois Institute of Technology in Chicago in 1982 and his Masters in Industrial Administration from Purdue University in 1983.
SATISH REDDY - DIRECTOR
Satish Reddy is the Chairman of Dr. Reddy’s Laboratories. He joined the company in 1993 and since then has held positions of increasing responsibility. Satish led the organization’s transition from a uni-focused manufacturer of APIs (active pharmaceutical ingredients) to a company that moved up the value-chain with a diverse product portfolio of Finished Dosage Formulations. He oversaw the expansion and establishing of a strong footprint for Dr. Reddy’s finished dosage products in Russia, CIS countries and other emerging markets. Satish holds a degree in Chemical Engineering from Osmania University, India, and an M.S. in Medicinal Chemistry from Purdue University, USA, where he received the 2009 Distinguished Alumnus Award from the School of Pharmacy and Pharmaceutical Sciences.
SAUMEN CHAKRAVARTY – DIRECTOR
Mr. Saumen Chakraborty is the President and Chief Financial Officer at Dr. Reddy’s. He has over 28 years of experience in both strategic and operational aspects of management. In his previous roles he has been associated with CMC, C-DOT, Eicher & Tecumseh. He is a Graduate in Physics from Visva-Bharati University and has a degree in Management from the Indian Institute of Management, Ahmedabad.
DR. BRUCE CARTER – INDEPENDENT DIRECTOR
Dr. Bruce LA Carter is an independent member of the board at Dr. Reddy’s for past 7 years. He started his long and illustrious career in the Biopharma industry at G.D. Searle & Co. In 1986 he joined ZymoGenetics as Vice President of Research and Development and then went on to head the company as Chief Executive Officer from April 1998 to January 2009. During this period ZymoGenetics was acquired by Novo Nordisk A/S where he served as Corporate Executive Vice President and Chief Scientific Officer from April 1994 to October 1999. Dr. Carter led the negotiations that established ZymoGenetics as an independent company from Novo Nordisk in 2000. He has also been the part of academia, as a Lecturer/Professor at Trinity College, University of Dublin and University of Washington. Dr. Carter received a B.Sc. with Honors in Botany from the University of Nottingham, England, and a Ph.D. in Microbiology from Queen Elizabeth College, University of London.
HARI BUGGANA - INDEPENDENT DIRECTOR
Mr. Hari Buggana is the Managing Director of InvAscent India – a private equity firm focused on Indian healthcare, pharma and medtech industries. Prior to this, Hari was a consultant with McKinsey & Company. During his stint at McKinsey, Hari primarily worked with life sciences businesses in the US, Europe, and India on a variety of issues ranging from corporate strategy, mergers & acquisitions, product-market strategy, R&D productivity, organizational effectiveness, and operations improvement. Prior to joining McKinsey, Hari worked as a scientist in the Pharmaceutical Products Division of Abbott Laboratories, USA. Hari has a MBA from Kellogg School of Management, Northwestern University and a M.S. in Chemical Engineering from Illinois Institute of Technology, Chicago.